Researchers Seek Pleural Effusions And Tissue to Create MCB Cell Lines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

BOSTON, Mass--Under a grant from the US Army Breast Cancer Program, Harvard researchers are attempting to create medullary carcinoma of the breast (MCB) cell lines as part of their immunologic studies. There is currently only one line in the world for this infrequent tumor. "We are especially interested in pleural effusions (or ascites)--the best source to make cell lines--but will also use fresh, unfixed tumor tissue, and will pay all shipping costs," said investigator Richard Junghans, PhD, MD.

BOSTON, Mass--Under a grant from the US Army Breast Cancer Program,Harvard researchers are attempting to create medullary carcinomaof the breast (MCB) cell lines as part of their immunologic studies.There is currently only one line in the world for this infrequenttumor. "We are especially interested in pleural effusions(or ascites)--the best source to make cell lines--but will alsouse fresh, unfixed tumor tissue, and will pay all shipping costs,"said investigator Richard Junghans, PhD, MD.

Departments are asked to post the request, which remains in effectuntil January 1, 1998. Prior to thoracentesis, or, when possible,tumor excision, please call Dr. Junghans or Dr. P. Telleman at617-632-0943; fax: 617-632-0998. (The MCB cell line is from theArmed Forces Institute of Pathology, Atlas #67-1-42.)

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content